Related Experiment Video

Updated: May 14, 2026

Concurrent Collection of Fetal Murine Brain and Serum to Assess Effects of Maternal Diet on Nutrition and Neurodevelopment in Neurofibromatosis Type 1
05:44

Concurrent Collection of Fetal Murine Brain and Serum to Assess Effects of Maternal Diet on Nutrition and Neurodevelopment in Neurofibromatosis Type 1

Published on: May 17, 2024

Impact of oral versus intravenous ibuprofen on neurodevelopmental outcome: a randomized controlled parallel study

Zeynep Eras1, Tulin Gokmen, Omer Erdeve

  • 1Developmental Behavioral Pediatrics Unit of Developmental Behavioral Pediatrics, Zekai Tahir Burak Maternity Teaching Hospital, Ankara, Turkey.

American Journal of Perinatology
|January 30, 2013
PubMed

Insights

Oral ibuprofen for patent ductus arteriosus in preterm infants showed similar long-term neurodevelopmental outcomes compared to intravenous ibuprofen. This study provides valuable data on the safety and efficacy of oral ibuprofen for this common condition.

Area of Science:

  • Neonatal medicine
  • Developmental pediatrics
  • Pharmacology

Background:

  • Patent ductus arteriosus (PDA) is common in preterm infants.
  • Intravenous indomethacin and ibuprofen are established PDA treatments.
  • Long-term neurodevelopmental effects of oral ibuprofen for PDA are not well-documented.

Purpose of the Study:

  • To compare the long-term neurodevelopmental outcomes of preterm infants treated with oral versus intravenous ibuprofen for PDA.
  • To assess neurological, neurosensory, and cognitive impairments at 18-24 months corrected age.

Main Methods:

  • Follow-up study of 99 infants (birth weight ≤ 1,500 g, gestational age ≤ 32 weeks) with PDA treated with oral or IV ibuprofen.
  • Neurodevelopmental outcomes assessed at 18-24 months corrected age.
  • Outcomes included cerebral palsy, hearing loss, blindness, and cognitive impairment (MDI < 70).

Main Results:

  • Long-term outcomes of 30 infants receiving oral ibuprofen were compared to 27 receiving IV ibuprofen.
  • No significant differences were found in neurological, neurosensory, or cognitive outcomes between the two groups.
  • Examiners were blinded to treatment group allocation.

Conclusions:

  • Oral ibuprofen for PDA in preterm infants results in similar neurodevelopmental outcomes at 2 years of age compared to intravenous ibuprofen.
  • Oral ibuprofen is a viable alternative treatment for PDA in preterm infants with comparable long-term neurodevelopmental profiles.
Abstract

More Related Videos

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale19:15

Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale

Published on: August 25, 2014

Related Concept Videos

Factors Affecting Drug Response: Overview01:21

Factors Affecting Drug Response: Overview

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...